

Author Index Volume 17 (2016)

The issue number is given in front of the pagination

- Abbas, S.M.A., see Enein, A.A.A. (2) 117–123
Abdelfaatah, R., see Enein, A.A.A. (2) 117–123
Abdelmoneim, S.S., see Osama, A. (2) 155–163
Adam, J., T. Sourisseau, K.A. Olaussen, A. Robin, C.Q. Zhu, A. Templier, A. Civet, P. Girard, V. Lazar, P. Validire, M.S. Tsao, J.-C. Soria and B. Besse, MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer (3) 323–333
Ai, Z., see Huang, Z. (4) 445–455
Akatsuka, Y., see Kobayashi, S. (1) 21–32
Akbari, A., see Mirzaei, A. (3) 301–311
Akers, J.C., V. Ramakrishnan, I. Yang, W. Hua, Y. Mao, B.S. Carter and C.C. Chen, Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid (2) 125–132
Alikanoğlu, A.S., see Kargı, A. (1) 17–20

Bae, D.-S., see Paik, E.S. (4) 419–425
Bagci, B., M. Sari, K. Karadayi, M. Turan, O. Ozdemir and G. Bagci, KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients (2) 133–143
Bagci, G., see Bagci, B. (2) 133–143
Bagheri, F., see Meshkat, M. (2) 213–222
Bai, Z.-M., see Lv, C. (1) 41–47
Balci, F.L., see Polat, A.K. (3) 293–300
Banys, L., see Juodzbaly, G. (4) 487–502
Bavor, P., see Halkova, T. (1) 97–106
Ben Ayed-Guerfali, D., S. Charfi, A. Khabir, T. Sellami-Boudawara, A. Gargouri and R. Mokdad-Gargouri, Clinical and prognosis relevance of COX-2 expression in Tunisian patients with primary gastric adenocarcinoma (1) 67–73
Bendlova, B., see Halkova, T. (1) 97–106
Besse, B., see Adam, J. (3) 323–333
Betka, J., see Halkova, T. (1) 97–106
Brawer, M., see Koch, M.O. (1) 83–88
Brown, J.A.L., see Clancy, C. (4) 427–435
Brunetto, A.L., see Portich, J.P. (3) 347–352
Brunetto, A.T., see Portich, J.P. (3) 347–352
Bychkov, V.A., see Kaigorodova, E.V. (2) 145–153

Cai, Y., see Yang, X.-P. (3) 271–279
Cai, Z.-G., see Li, S.-X. (4) 377–382
Cao, L., see Wang, L. (4) 463–471
Carter, B.S., see Akers, J.C. (2) 125–132
Cereda, V., see Formica, V. (3) 335–345
Chaix, C., see Ittel, A. (4) 405–409
Charfi, S., see Ben Ayed-Guerfali, D. (1) 67–73
Chen, C.C., see Akers, J.C. (2) 125–132
Chen, D., see Zhang, K. (3) 281–291
Chen, D.-T., see Chen, Y.-F. (1) 89–96
Chen, S., see Xia, H. (2) 165–170
Chen, X., see Yang, B. (2) 223–230
Chen, Y.-F., Q. Li, D.-T. Chen, J.-H. Pan, Y.-H. Chen, Z.-S. Wen and W.-A. Zeng, Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy (1) 89–96
Chen, Y.-H., see Chen, Y.-F. (1) 89–96
Chen, Z., see He, A. (2) 231–236
Cheng, L., see Koch, M.O. (1) 83–88
Cho, J.S., see Koch, M.O. (1) 83–88
Choi, C.H., see Paik, E.S. (4) 419–425
Choi, H.J., see Paik, E.S. (4) 419–425
Choynzonov, E.L., see Kaigorodova, E.V. (2) 145–153
Cicciù, M., see Juodzbaly, G. (4) 487–502
Civet, A., see Adam, J. (3) 323–333
Clancy, C., S. Khan, C.L. Glynn, E. Holian, P. Dockery, P. Lalor, J.A.L. Brown, M.R. Joyce, M.J. Kerin and R.M. Dwyer, Screening of exosomal microRNAs from colorectal cancer cells (4) 427–435

- de Farias, C.B., see Portich, J.P. (3) 347–352
 Demirpençe, Ö., see Kargı, A. (1) 17–20
 Di Loreto, C., see Orsaria, M. (4) 479–486
 Diep, G.K., see Khan, F. (4) 457–462
 Ding, K., see Yang, B. (2) 223–230
 Ding, Q.-J., see Gong, L. (2) 195–204
 Dockery, P., see Clancy, C. (4) 427–435
 Dong, A., see Zhang, K. (3) 281–291
 dos Santos, R.P., see Portich, J.P. (3) 347–352
 Duan, H., see Lu, L. (2) 171–177
 Dvorakova, S., see Halkova, T. (1) 97–106
 Dwyer, R.M., see Clancy, C. (4) 427–435
 Dziki, Ł., see Włodarczyk, M. (4) 411–417
 Dziki, A., see Włodarczyk, M. (4) 411–417
- El Sharkawy, N., see Enein, A.A.A. (2) 117–123
 Elhamid, S.A., see Enein, A.A.A. (2) 117–123
 Enein, A.A.A., H.A.A. Rahman, N. El Sharkawy, S.A. Elhamid, S.M.A. Abbas, R. Abdelfaatah, M. Khalil and L.A. Fathalla, Significance of CD99 expression in T-lineage acute lymphoblastic leukemia (2) 117–123
- Fan, L., see Wu, J.-Z. (2) 205–212
 Fathalla, L.A., see Enein, A.A.A. (2) 117–123
 Feng, Y., see Miao, Y. (1) 33–40
 Ferreira, M.B.C., see Portich, J.P. (3) 347–352
 Ferroni, P., see Formica, V. (3) 335–345
 Formica, V., C. Morelli, P. Ferroni, A. Nardecchia, M. Tesauero, S. Pellicori, V. Cereda, A. Russo, S. Riondino, F. Guadagni and M. Roselli, Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin (3) 335–345
- Galindo-Moreno, P., see Juodzbaly, G. (4) 487–502
 Gao, D., see Zhou, H. (1) 1–10
 Gao, S., see Wang, J. (4) 369–376
 Gao, X., see Huang, Z. (4) 445–455
 Gao, X., see Wen, X. (3) 313–322
 Gargouri, A., see Ben Ayed-Guerfali, D. (1) 67–73
 Ghaedi, K., see Meshkat, M. (2) 213–222
 Gil, M.S., see Portich, J.P. (3) 347–352
 Girard, P., see Adam, J. (3) 323–333
 Glynn, C.L., see Clancy, C. (4) 427–435
 Göktaş, S., see Kargı, A. (1) 17–20
 Gong, L., Y. Xu, Y.-Q. Hu, Q.-J. Ding, C.-H. Yi, W. Huang and M. Zhou, *hTERT* gene polymorphism correlates with the risk and the prognosis of thyroid cancer (2) 195–204
 Goulart, B.K., see Portich, J.P. (3) 347–352
 Gregianin, L.J., see Portich, J.P. (3) 347–352
- Guadagni, F., see Formica, V. (3) 335–345
 Guan, Y., see Shi, Z.-W. (2) 249–257
 Gündüz, Ş., see Kargı, A. (1) 17–20
 Guo, L., see Wen, X. (3) 313–322
 Guobis, Z., see Juodzbaly, G. (4) 487–502
- Halkova, T., S. Dvorakova, V. Sykorova, E. Vaclavikova, J. Vcelak, P. Vlcek, P. Sykorova, D. Kodetova, J. Betka, P. Lastuvka, P. Bavor, J. Hoch, R. Katra and B. Bendlova, Polymorphisms in selected DNA repair genes and cell cycle regulating genes involved in the risk of papillary thyroid carcinoma (1) 97–106
 Hao, F., see Zhang, K. (3) 281–291
 Hassany, S.M., see Osama, A. (2) 155–163
 Hata, T., see Kobayashi, S. (1) 21–32
 He, A., Z. Chen, H. Mei and Y. Liu, Decreased expression of LncRNA MIR31HG in human bladder cancer (2) 231–236
 He, W., see Shi, Z.-W. (2) 249–257
 Hermanova, M., see Zambo, I. (1) 107–116
 Hoch, J., see Halkova, T. (1) 97–106
 Holian, E., see Clancy, C. (4) 427–435
 Hrabák, P., see Rychlíková, J. (1) 55–65
 Hu, Y.-Q., see Gong, L. (2) 195–204
 Hua, W., see Akers, J.C. (2) 125–132
 Huang, H., see Xia, H. (2) 165–170
 Huang, W., see Gong, L. (2) 195–204
 Huang, W., see Yang, B. (2) 223–230
 Huang, Y., see Lv, C. (1) 41–47
 Huang, Y., see Wu, J.-Z. (2) 205–212
 Huang, Z., see Zhou, X. (3) 359–367
 Huang, Z., Z. Ai, N. Li, H. Xi, X. Gao, F. Wang, X. Tan and H. Liu, Over expression of galectin-3 associates with short-term poor prognosis in stage II colon cancer (4) 445–455
- Ito, Y., see Kobayashi, S. (1) 21–32
 Ittel, A., H. Zattara, C. Chaix, G. Michel and N. Levy, Molecular combing: A new tool in diagnosing leukemia (4) 405–409
- Jáchymová, M., see Rychlíková, J. (1) 55–65
 Jin, L.-J., see Li, S.-X. (4) 377–382
 Johnson, R., see Polat, A.K. (3) 293–300
 Joyce, M.R., see Clancy, C. (4) 427–435
 Juodzbaly, G., D. Kasradze, M. Cicciù, A. Sudeikis, L. Banys, P. Galindo-Moreno and Z. Guobis, Modern molecular biomarkers of head and neck cancer. Part I. Epigenetic diagnostics and prognostics: Systematic review (4) 487–502

- Kadijani, A.A., see Mirzaei, A. (3) 301–311
- Kaigorodova, E.V., M.V. Zavyalova, V.A. Bychkov, V.M. Perelmuter and E.L. Choyznzonov, Functional state of the Hsp27 chaperone as a molecular marker of an unfavorable course of larynx cancer (2) 145–153
- Kaimakliotis, H.Z., see Koch, M.O. (1) 83–88
- Kakumoto, K., see Kobayashi, S. (1) 21–32
- Kanbour-Shakir, A., see Polat, A.K. (3) 293–300
- Kang, X.-L., see Yang, B. (2) 223–230
- Karadayi, K., see Bagci, B. (2) 133–143
- Kargı, A., Ö. Demirpençe, Ş. Gündüz, S. Göktaş, A.S. Alikanoğlu and M. Yıldırım, Serum levels of HMGB1 have a diagnostic role in metastatic renal cell cancer (1) 17–20
- Kasprzyk, J., see Włodarczyk, M. (4) 411–417
- Kasradze, D., see Juodzbalyš, G. (4) 487–502
- Katra, R., see Halkova, T. (1) 97–106
- Kerin, M.J., see Clancy, C. (4) 427–435
- Keum, D.Y., see Lee, D.H. (4) 473–478
- Khabir, A., see Ben Ayed-Guerfali, D. (1) 67–73
- Khalil, M., see Enein, A.A.A. (2) 117–123
- Khan, F., R.I. Vogel, G.K. Diep, T.M. Tuttle and E. Lou, Prognostic factors for survival in advanced appendiceal cancers (4) 457–462
- Khan, S., see Clancy, C. (4) 427–435
- Khorasani, M., see Shahbazi, S. (3) 353–358
- Kim, B.-G., see Paik, E.S. (4) 419–425
- Kim, D.-K., see Lee, D.H. (4) 473–478
- Kim, T.-J., see Paik, E.S. (4) 419–425
- Kobayashi, S., Y. Ueda, Y. Nannya, H. Shibayama, H. Tamura, K. Ogata, Y. Akatsuka, K. Usuki, Y. Ito, M. Okada, T. Suzuki, T. Hata, A. Matsuda, K. Tohyama, K. Kakumoto, D. Koga, K. Mitani, T. Naoe, H. Sugiyama and F. Takaku, Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes (1) 21–32
- Koch, M.O., J.S. Cho, H.Z. Kaimakliotis, L. Cheng, Z. Sangale, M. Brawer, W. Welbourn, J. Reid and S. Stone, Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence (1) 83–88
- Kodetova, D., see Halkova, T. (1) 97–106
- Koga, D., see Kobayashi, S. (1) 21–32
- Krechler, T., see Rychlíková, J. (1) 55–65
- Kyr, M., see Zambo, I. (1) 107–116
- Lalor, P., see Clancy, C. (4) 427–435
- Lastuvka, P., see Halkova, T. (1) 97–106
- Lazar, V., see Adam, J. (3) 323–333
- Lee, D.H., J.-H. Lee, D.Y. Keum and D.-K. Kim, Variable alterations of mitochondrial microsatellite instability and DNA copy number in pulmonary hamartomas (4) 473–478
- Lee, J.-H., see Lee, D.H. (4) 473–478
- Lee, J.-W., see Paik, E.S. (4) 419–425
- Lee, Y.-Y., see Paik, E.S. (4) 419–425
- Levy, N., see Ittel, A. (4) 405–409
- Li, B., see Miao, Y. (1) 33–40
- Li, D., see Yang, Z. (4) 437–444
- Li, D., see Yao, H. (4) 397–404
- Li, H., see Yang, J. (2) 237–247
- Li, J.-Y., see Wu, J.-Z. (2) 205–212
- Li, N., see Huang, Z. (4) 445–455
- Li, Q., see Chen, Y.-F. (1) 89–96
- Li, Q.-L., Y. Yang, L. Zhang, D. Pan and W.-J. Xie, MicroRNA-181b inhibits glycolysis in gastric cancer cells via targeting hexokinase 2 gene (1) 75–81
- Li, S., see Miao, Y. (1) 33–40
- Li, S.-X., Y.-Q. Yang, L.-J. Jin, Z.-G. Cai and Z. Sun, Detection of survivin, carcinoembryonic antigen and ErbB2 level in oral squamous cell carcinoma patients (4) 377–382
- Liang, J.-H., see Wu, J.-Z. (2) 205–212
- Lin, F., see Xu, J.-N. (1) 11–16
- Lin, Q.-F., see Xu, J.-N. (1) 11–16
- Liu, H., see Huang, Z. (4) 445–455
- Liu, J., see Zhang, K. (2) 187–194
- Liu, L., see Yang, X.-P. (3) 271–279
- Liu, L., see Yin, R. (3) 259–269
- Liu, L., see Zhang, K. (2) 187–194
- Liu, P., see Zhou, X. (3) 359–367
- Liu, W., see Lu, L. (2) 171–177
- Liu, Y., see He, A. (2) 231–236
- Liu, Z., see Yang, B. (2) 223–230
- Liu, Z., see Yang, L. (2) 179–185
- Liu, Z., see Yang, Z. (4) 437–444
- Liu, Z., see Yao, H. (4) 397–404
- Liu, Z.-X., see Lv, C. (1) 41–47
- Londero, A.P., see Orsaria, M. (4) 479–486
- Loss, J.F., see Portich, J.P. (3) 347–352
- Lou, E., see Khan, F. (4) 457–462
- Lu, C., see Xu, J.-N. (1) 11–16
- Lu, L., Y. Shen, K.-F. Tseng, W. Liu, H. Duan and W. Meng, Silencing of UCA1, a poor prognostic factor, inhibited the migration of endometrial cancer cell (2) 171–177
- Lu, R., see Wen, X. (3) 313–322
- Luo, Z., see Zhang, K. (2) 187–194

- Lv, C., Y. Huang, Z.-X. Liu, D. Yu and Z.-M. Bai, Salidroside reduces renal cell carcinoma proliferation by inhibiting JAK2/STAT3 signaling (1) 41–47
- Lv, Q., see Yang, J. (2) 237–247
- Ma, H., see Wang, L. (4) 463–471
- Ma, H., see Xia, H. (2) 165–170
- Ma, L., see Wang, L. (4) 463–471
- Ma, S.-L., see Yang, X.-P. (3) 271–279
- Macáček, J., see Rychlíková, J. (1) 55–65
- Maden, M., O.N. Pamuk and G.E. Pamuk, High apelin levels could be used as a diagnostic marker in multiple myeloma: A comparative study (4) 391–396
- Madjd, Z., see Mirzaei, A. (3) 301–311
- Mahdian, R., see Shahbazi, S. (3) 353–358
- Mao, W.-D., see Xu, J.-N. (1) 11–16
- Mao, Y., see Akers, J.C. (2) 125–132
- Marchesoni, D., see Orsaria, M. (4) 479–486
- Mariuzzi, L., see Orsaria, M. (4) 479–486
- Marzinotto, S., see Orsaria, M. (4) 479–486
- Matsuda, A., see Kobayashi, S. (1) 21–32
- Mei, H., see He, A. (2) 231–236
- Menekse, E., see Polat, A.K. (3) 293–300
- Meng, W., see Lu, L. (2) 171–177
- Meng, W., see Yang, J. (2) 237–247
- Meshkat, M., H.M. Tanha, M.M. Naeini, K. Ghaedi, M.H. Sanati, M. Meshkat and F. Bagheri, Functional SNP in stem of mir-146a affects Her2 status and breast cancer survival (2) 213–222
- Meshkat, M., see Meshkat, M. (2) 213–222
- Miao, X., see Yang, Z. (4) 437–444
- Miao, X., see Yao, H. (4) 397–404
- Miao, Y., Q. Yan, S. Li, B. Li and Y. Feng, Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy (1) 33–40
- Miao, Y., see Wu, J.-Z. (2) 205–212
- Michel, G., see Ittel, A. (4) 405–409
- Min, W., see Zhou, H. (1) 1–10
- Mirzaei, A., Z. Madjd, A.A. Kadijani, M. Tavakoli-Yaraki, M.H. Modarresi, J. Verdi, A. Akbari and G. Tavoosidana, Evaluation of circulating cellular DCLK1 protein, as the most promising colorectal cancer stem cell marker, using immunoassay based methods (3) 301–311
- Mitani, K., see Kobayashi, S. (1) 21–32
- Modarresi, M.H., see Mirzaei, A. (3) 301–311
- Mokdad-Gargouri, R., see Ben Ayed-Guerfali, D. (1) 67–73
- Morelli, C., see Formica, V. (3) 335–345
- Mudry, P., see Zambo, I. (1) 107–116
- Naeini, M.M., see Meshkat, M. (2) 213–222
- Nannya, Y., see Kobayashi, S. (1) 21–32
- Naoue, T., see Kobayashi, S. (1) 21–32
- Nardecchia, A., see Formica, V. (3) 335–345
- Ni, W., see Wang, J. (4) 369–376
- Ning, H., see Yang, B. (2) 223–230
- Ogata, K., see Kobayashi, S. (1) 21–32
- Okada, M., see Kobayashi, S. (1) 21–32
- Olaussen, K.A., see Adam, J. (3) 323–333
- Orsaria, M., A.P. Londero, S. Marzinotto, C. Di Loreto, D. Marchesoni and L. Mariuzzi, Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma (4) 479–486
- Osama, A., D. Sabry, S.M. Hassany, S.S. Abdelmoneim and A. Sabry, SIRT-1 expression is associated with expression of NANOG in patients with colorectal adenocarcinoma (2) 155–163
- Ozdemir, O., see Bagci, B. (2) 133–143
- Paik, E.S., M. Shim, H.J. Choi, Y.-Y. Lee, T.-J. Kim, C.H. Choi, J.-W. Lee, B.-G. Kim and D.-S. Bae, Preoperative multiplication of neutrophil and monocyte counts as a prognostic factor in epithelial ovarian cancer (4) 419–425
- Pamuk, G.E., see Maden, M. (4) 391–396
- Pamuk, O.N., see Maden, M. (4) 391–396
- Pan, D., see Li, Q.-L. (1) 75–81
- Pan, D., see Yang, B. (2) 223–230
- Pan, J.-H., see Chen, Y.-F. (1) 89–96
- Pellicori, S., see Formica, V. (3) 335–345
- Perelmuter, V.M., see Kaigorodova, E.V. (2) 145–153
- Polat, A.K., A. Soran, A. Kanbour-Shakir, E. Menekse, F.L. Balci and R. Johnson, The role of molecular biomarkers for predicting adjacent breast cancer of Atypical Ductal Hyperplasia diagnosed on core biopsy (3) 293–300
- Portich, J.P., M.S. Gil, R.P. dos Santos, B.K. Goulart, M.B.C. Ferreira, J.F. Loss, L.J. Gregianin, A.L. Brunetto, A.T. Brunetto, R. Roesler and C.B. de Farias, Low brain-derived neurotrophic factor levels are associated with active disease and poor prognosis in childhood acute leukemia (3) 347–352

- Qu, J. and X. Qu, The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer (1) 49–54
- Qu, X., see Qu, J. (1) 49–54
- Qu, X.-Y., see Wu, J.-Z. (2) 205–212
- Rahman, H.A.A., see Enein, A.A.A. (2) 117–123
- Ramakrishnan, V., see Akers, J.C. (2) 125–132
- Reid, J., see Koch, M.O. (1) 83–88
- Riondino, S., see Formica, V. (3) 335–345
- Robin, A., see Adam, J. (3) 323–333
- Roesler, R., see Portich, J.P. (3) 347–352
- Roselli, M., see Formica, V. (3) 335–345
- Russo, A., see Formica, V. (3) 335–345
- Rychlíková, J., M. Vecka, M. Jáchymová, J. Macášek, P. Hrabák, M. Zeman, L. Vávrová, J. Šoupal, T. Krechler and A. Žák, Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis (1) 55–65
- Sabry, A., see Osama, A. (2) 155–163
- Sabry, D., see Osama, A. (2) 155–163
- Sanati, M.H., see Meshkat, M. (2) 213–222
- Sangale, Z., see Koch, M.O. (1) 83–88
- Sari, M., see Bagci, B. (2) 133–143
- Sellami-Boudawara, T., see Ben Ayed-Guerfali, D. (1) 67–73
- Shahbazi, S., M. Khorasani and R. Mahdian, Gene expression profile of *FVII* and *AR* in primary prostate cancer (3) 353–358
- Shen, D., see Xu, J.-N. (1) 11–16
- Shen, J., see Xia, H. (2) 165–170
- Shen, Y., see Lu, L. (2) 171–177
- Shi, Z.-W., J.-L. Wang, N. Zhao, Y. Guan and W. He, Single nucleotide polymorphism of *hsa-miR-124a* affects risk and prognosis of osteosarcoma (2) 249–257
- Shibayama, H., see Kobayashi, S. (1) 21–32
- Shim, M., see Paik, E.S. (4) 419–425
- Skoda, J., see Zambo, I. (1) 107–116
- Sobolewska-Włodarczyk, A., see Włodarczyk, M. (4) 411–417
- Song, X., see Zhang, K. (2) 187–194
- Soran, A., see Polat, A.K. (3) 293–300
- Soria, J.-C., see Adam, J. (3) 323–333
- Šoupal, J., see Rychlíková, J. (1) 55–65
- Sourisseau, T., see Adam, J. (3) 323–333
- Sterba, J., see Zambo, I. (1) 107–116
- Stone, S., see Koch, M.O. (1) 83–88
- Su, H., see Yin, R. (3) 259–269
- Sudeikis, A., see Juodzbalys, G. (4) 487–502
- Sugiyama, H., see Kobayashi, S. (1) 21–32
- Sun, C., see Yin, R. (3) 259–269
- Sun, J., see Wen, X. (3) 313–322
- Sun, Z., see Li, S.-X. (4) 377–382
- Suzuki, T., see Kobayashi, S. (1) 21–32
- Sykorova, P., see Halkova, T. (1) 97–106
- Sykorova, V., see Halkova, T. (1) 97–106
- Tai, G., see Wang, J. (4) 369–376
- Takaku, F., see Kobayashi, S. (1) 21–32
- Tamura, H., see Kobayashi, S. (1) 21–32
- Tan, X., see Huang, Z. (4) 445–455
- Tanha, H.M., see Meshkat, M. (2) 213–222
- Tavakoli-Yaraki, M., see Mirzaei, A. (3) 301–311
- Tavoosidana, G., see Mirzaei, A. (3) 301–311
- Tchórzewski, M., see Włodarczyk, M. (4) 411–417
- Templier, A., see Adam, J. (3) 323–333
- Tesaro, M., see Formica, V. (3) 335–345
- Tian, T., see Wu, J.-Z. (2) 205–212
- Tohyama, K., see Kobayashi, S. (1) 21–32
- Tsao, M.S., see Adam, J. (3) 323–333
- Tseng, K.-F., see Lu, L. (2) 171–177
- Turan, M., see Bagci, B. (2) 133–143
- Tuttle, T.M., see Khan, F. (4) 457–462
- Ueda, Y., see Kobayashi, S. (1) 21–32
- Usuki, K., see Kobayashi, S. (1) 21–32
- Vaclavikova, E., see Halkova, T. (1) 97–106
- Validire, P., see Adam, J. (3) 323–333
- Vávrová, L., see Rychlíková, J. (1) 55–65
- Vcelak, J., see Halkova, T. (1) 97–106
- Vecka, M., see Rychlíková, J. (1) 55–65
- Verdi, J., see Mirzaei, A. (3) 301–311
- Veselska, R., see Zambo, I. (1) 107–116
- Vlcek, P., see Halkova, T. (1) 97–106
- Vogel, R.I., see Khan, F. (4) 457–462
- Wang, F., see Huang, Z. (4) 445–455
- Wang, H., see Wen, X. (3) 313–322
- Wang, J., S. Zhang, W. Ni, X. Zhai, F. Xie, H. Yuan, S. Gao and G. Tai, Development and application of a double-antibody sandwich ELISA kit for the detection of serum MUC1 in lung cancer patients (4) 369–376
- Wang, J.-L., see Shi, Z.-W. (2) 249–257
- Wang, L., H. Ma, L. Zhu, L. Ma, L. Cao, H. Wei and J. Xu, Screening for the optimal gene and functional gene sets related to breast cancer using differential co-expression and differential expression analysis (4) 463–471
- Wang, L., see Wu, J.-Z. (2) 205–212
- Wang, R., see Yang, J. (2) 237–247

- Wang, T., see Yang, L. (2) 179–185
- Wang, X., see Yang, L. (2) 179–185
- Wang, Y., see Wen, X. (3) 313–322
- Wang, Y., see Yang, B. (2) 223–230
- Wei, H., see Wang, L. (4) 463–471
- Welbourn, W., see Koch, M.O. (1) 83–88
- Wen, Z.-S., see Chen, Y.-F. (1) 89–96
- Wen, X., R. Lu, S. Xie, H. Zheng, H. Wang, Y. Wang, J. Sun, X. Gao and L. Guo, *APE1* overexpression promotes the progression of ovarian cancer and serves as a potential therapeutic target (3) 313–322
- Włodarczyk, J., see Włodarczyk, M. (4) 411–417
- Włodarczyk, M., J. Kasprzyk, A. Sobolewska-Włodarczyk, J. Włodarczyk, M. Tchórzewski, A. Dziki and Ł. Dziki, Mean platelet volume as a possible biomarker of tumor progression in rectal cancer (4) 411–417
- Wu, J.-Z., T. Tian, Y. Huang, J.-H. Liang, Y. Miao, L. Wang, J. Xu, X.-Y. Qu, L. Fan, J.-Y. Li and W. Xu, Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma (2) 205–212
- Wu, L., see Zhang, K. (2) 187–194
- Xi, H., see Huang, Z. (4) 445–455
- Xia, H., J. Shen, S. Chen, H. Huang, Y. Xu and H. Ma, Overexpression of VEGF-C correlates with a poor prognosis in esophageal cancer patients (2) 165–170
- Xie, F., see Wang, J. (4) 369–376
- Xie, S., see Wen, X. (3) 313–322
- Xie, W.-J., see Li, Q.-L. (1) 75–81
- Xu, J., see Wang, L. (4) 463–471
- Xu, J., see Wu, J.-Z. (2) 205–212
- Xu, J.-N., D. Shen, W.-D. Mao, Q.-F. Lin, F. Lin and C. Lu, The effects of PK11195 on the MCF-7 and T47D were associated with the allopregnanolone biosynthesis, which was mediated by Translocator Protein 18 Kda (1) 11–16
- Xu, L., see Zhou, X. (3) 359–367
- Xu, W., see Wu, J.-Z. (2) 205–212
- Xu, Y., see Gong, L. (2) 195–204
- Xu, Y., see Xia, H. (2) 165–170
- Yan, Q., see Miao, Y. (1) 33–40
- Yang, B., Z. Liu, H. Ning, K. Zhang, D. Pan, K. Ding, W. Huang, X.-L. Kang, Y. Wang and X. Chen, MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer (2) 223–230
- Yang, H.-S., Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations (4) 383–389
- Yang, I., see Akers, J.C. (2) 125–132
- Yang, J., R. Wang, H. Li, Q. Lv, W. Meng and X. Yang, Lentivirus mediated RNA interference of EMMPRIN (CD147) gene inhibits the proliferation, matrigel invasion and tumor formation of breast cancer cells (2) 237–247
- Yang, J., see Zhang, K. (2) 187–194
- Yang, L., see Yang, Z. (4) 437–444
- Yang, L., see Yao, H. (4) 397–404
- Yang, L., T. Wang, J. Zhang, Z. Liu and X. Wang, Expression of BTBD7 in primary salivary adenoid cystic carcinoma and correlation with Slug and prognosis (2) 179–185
- Yang, Q.-J., see Yang, X.-P. (3) 271–279
- Yang, T., see Yin, R. (3) 259–269
- Yang, X., see Yang, J. (2) 237–247
- Yang, X.-P., L.-X. Zhou, Q.-J. Yang, L. Liu, Y. Cai and S.-L. Ma, Diagnostic and prognostic roles of serum vitronectin in hepatitis B-related hepatocellular carcinoma (3) 271–279
- Yang, Y., see Li, Q.-L. (1) 75–81
- Yang, Y.-Q., see Li, S.-X. (4) 377–382
- Yang, Z., D. Li, Z. Liu, X. Miao, L. Yang, Q. Zou and Y. Yuan, BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance (4) 437–444
- Yang, Z., see Yao, H. (4) 397–404
- Yao, H., Z. Yang, Z. Liu, X. Miao, L. Yang, D. Li, Q. Zou and Y. Yuan, Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma (4) 397–404
- Yi, C.-H., see Gong, L. (2) 195–204
- Yıldırım, M., see Kargı, A. (1) 17–20
- Yin, R., T. Yang, H. Su, L. Ying, L. Liu and C. Sun, Saturated fatty acids as possible important metabolites for epithelial ovarian cancer based on the free and esterified fatty acid profiles determined by GC-MS analysis (3) 259–269
- Ying, L., see Yin, R. (3) 259–269
- Yu, D., see Lv, C. (1) 41–47
- Yu, M., see Zhang, K. (3) 281–291
- Yu, Q., see Zhou, H. (1) 1–10
- Yuan, H., see Wang, J. (4) 369–376
- Yuan, M., see Zhou, H. (1) 1–10
- Yuan, Y., see Yang, Z. (4) 437–444
- Yuan, Y., see Yao, H. (4) 397–404

- Žák, A., see Rychlíková, J. (1) 55–65
- Zambo, I., M. Hermanova, D. Zapletalova, J. Skoda, P. Mudry, M. Kyr, K. Zitterbart, J. Sterba and R. Veselska, Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas (1) 107–116
- Zapletalova, D., see Zambo, I. (1) 107–116
- Zattara, H., see Ittel, A. (4) 405–409
- Zavyalova, M.V., see Kaigorodova, E.V. (2) 145–153
- Zeman, M., see Rychlíková, J. (1) 55–65
- Zeng, W.-A., see Chen, Y.-F. (1) 89–96
- Zhai, X., see Wang, J. (4) 369–376
- Zhang, H., see Zhou, X. (3) 359–367
- Zhang, J., see Yang, L. (2) 179–185
- Zhang, K., M. Yu, F. Hao, A. Dong and D. Chen, Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells *in vitro* and *in vivo* (3) 281–291
- Zhang, K., see Yang, B. (2) 223–230
- Zhang, K., Z. Luo, Y. Zhang, L. Zhang, L. Wu, L. Liu, J. Yang, X. Song and J. Liu, Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer (2) 187–194
- Zhang, L., see Li, Q.-L. (1) 75–81
- Zhang, L., see Zhang, K. (2) 187–194
- Zhang, L., see Zhou, X. (3) 359–367
- Zhang, S., see Wang, J. (4) 369–376
- Zhang, Y., see Zhang, K. (2) 187–194
- Zhao, N., see Shi, Z.-W. (2) 249–257
- Zheng, H., see Wen, X. (3) 313–322
- Zhou, H., M. Yuan, Q. Yu, X. Zhou, W. Min and D. Gao, Autophagy regulation and its role in gastric cancer and colorectal cancer (1) 1–10
- Zhou, L.-X., see Yang, X.-P. (3) 271–279
- Zhou, M., see Gong, L. (2) 195–204
- Zhou, X., L. Xu, Z. Huang, L. Zhang, H. Zhang, W. Zhu and P. Liu, The hematologic markers as prognostic factors in patients with resectable gastric cancer (3) 359–367
- Zhou, X., see Zhou, H. (1) 1–10
- Zhu, C.Q., see Adam, J. (3) 323–333
- Zhu, L., see Wang, L. (4) 463–471
- Zhu, W., see Zhou, X. (3) 359–367
- Zitterbart, K., see Zambo, I. (1) 107–116
- Zou, Q., see Yang, Z. (4) 437–444
- Zou, Q., see Yao, H. (4) 397–404